News

In case you missed it, this week we had news about pregnancy-related skin changes, art in clinical spaces, Allergan's upcoming skin quality index, and more.

This week, we feature top articles from our sister publications on the future of health care, FDA approvals, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Allergan’s latest initiative hopes to empower both patients and clinicians while advancing industry standards, according to Sherket Peterson, PhD.

A cross-sectional survey revealed that many patients with HS are dissatisfied with treatment options, with gaps in knowledge about FDA-approved therapies.

The study found dupilumab-treated patients had the highest probability of remaining infection-free over 52 weeks.

Sherket Peterson, PhD, spoke to Dermatology Times about Allergan’s recent research and plan to launch a universal skin quality index.

Studies show that exposure to meaningful artwork can lower blood pressure and enhance mental clarity in patients.

Tremfya is the first IL-23 inhibitor to significantly improve both symptoms and structural damage in active psoriatic arthritis.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Unlike biologics, nonbiologic systemic therapies showed a neutral or slightly increased cardiovascular risk, raising concerns about their long-term safety.

Jiyeon Oh’s research confirms that a personalized approach is needed to treat all complexities associated with AD.

Researchers reported the case of a 28-year-old woman with epidermodysplasia verruciformis who developed SCC on a sun-protected scalp.

The study stated early recognition and aggressive treatment of childhood-onset MMP are essential to prevent permanent scarring.

Researcher Jiyeon Oh shares results of a recent study that confirm the prevalence of AD is stable, but disease burden is rising.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Hand eczema affects 22.4% of adults in East Greenland, with prevalence, severity, and risk factors mirroring trends other populations.

Get a glimpse of the cutting-edge atopic dermatitis research, breakthroughs, and insights to be presented at the 7th RAD Annual Meeting, June 6-7, 2025.

Positive changes in DLQI scores were observed after 4 weeks of therapy as well as the 6-month follow-up.

Researchers call for standardized methods to assess and report ADWEs in deprescribing trials to ensure reliable data and clinical confidence.

Bio-naïve patients and those without comorbidities had the highest treatment success rates with guselkumab.

Misinformation from outside sources creates unrealistic expectations for pregnancy and postpartum skin conditions like hyperpigmentation.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Gooderham continues a discussion on new data reinforcing the safety of topical delgocitinib, with minimal systemic absorption even under maximal use conditions.

2% and 4% formulations of the product were effective and tolerable for patients with varying scalp conditions.

Microbiome engineering offers strategies to modulate the skin microbiome, including non-targeted approaches like probiotics and targeted approaches like phage therapy.

Nearly all patients saw improvements in small, medium, and large depressions on the cheeks and temples with just a singular treatment session.

The significance of patient education and setting realistic expectations for the often-slow process of repigmentation in vitiligo treatment was a key focus of the discussion.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of April.

Catch up on dermatology news, highlights, and insights from the past 24 hours.